Table 4.
Evolution of quality indicators as formulated by EUSOMA prospectively evaluated between 2003 and 2010 (data for first semester)
| Outcome measure | 2003 | 2010 | P value | ||||
|---|---|---|---|---|---|---|---|
| |
EUSOMA |
|
|
|
|
|
|
| |
Minimum standard |
Target |
N |
% |
N |
% |
|
| Positive preoperative cyto/histological diagnosis |
|
|
77/130 |
59.7% |
161/183 |
88.4% |
0.0001 |
| |
80% |
90% |
|
|
|
|
|
| Operated invasive carcinoma for which hist. type, grading ER/PR, stage and size were recorded |
|
|
106/112 |
94.6% |
178/181 |
98.3% |
0.1467 |
| |
90% |
95% |
|
|
|
|
|
| Operated non invasive carcinoma for which size, histological type and grading are recorded |
|
|
5/7 |
71% |
28/29 |
96.5% |
0.4966 |
| |
95% |
98% |
|
|
|
|
|
| More than 9 lymph nodes removed when ALD performed (excluding sampling) |
|
|
97/112 |
85.6% |
67/70 |
95.7% |
0.0434 |
| |
95% |
98% |
|
|
|
|
|
| Postoperative radiotherapy in M0 invasive CA with BCT |
|
|
50/51 |
98% |
105/108 |
97.2% |
0.7588 |
| |
90% |
95% |
|
|
|
|
|
| BCT in invasive carcinoma with total size up to 30 mm (including DCIS component) |
|
|
49/79 |
62% |
86/104 |
82.6% |
0.0016 |
| |
70% |
80% |
|
|
|
|
|
| BCT in carcinoma in situ up to 20 mm |
|
|
3/7 |
43.8% |
11/14 |
78.6 |
0.0016 |
| |
70% |
80% |
|
|
|
|
|
| Ductal carcinoma in situ without axillary dissection |
|
|
6/7 |
85.7% |
22/23 |
95.6% |
0.3560 |
| |
80% |
90% |
|
|
|
|
|
| Hormonotherapy in endocrine sensitive invasive carcinoma |
|
|
89/105 |
84.8% |
151/155 |
97.4% |
0.0002 |
| |
80% |
90% |
|
|
|
|
|
| Adjuvant chemotherapy in ER- (PT1c+ or N+) invasive Carcinoma |
|
|
18/25 |
72% |
22/23 |
95.6% |
0.0280 |
| 80% | 90% |
N: number of patients; %: percentage of successful outcome measure/total number of cases; ER: estrogen receptor; PR: progesterone receptor; ALD: axillary lymph node dissection; BCT: breast conserving therapy; DCIS: ductal carcinoma in situ; significance level calculated with two-tailed χ2 test without Yates correction.